|
|
|||||||||||||||||
|
|
|
NISTIR
6917 IV. Summary ProfileSection IV provides
a detailed profile of the projects and organizations included in the study
to establish linkages between the analytical models and technology and
business goals and characteristics of ATP-funded companies. A. Overview of Technology
Areas and Targeted Industrial Sectors
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Number
of projects
|
Number
of project participants
|
Number
of commercial applications
|
|
| All |
299
|
558
|
1,172
|
| Matched Baseline Reports and Close-out Reports |
147
|
176
|
301
|
| Matched Post-project Surveys |
134*
|
173*
|
104
|
The dataset for the 558 participants in 299 projects reflects 81% of all ATP awards and 63% of all project participants in awards made 19931998. Some participants of very large ATP joint ventures are relieved from the ATP business reporting responsibility, and non-profit organizations without R&D responsibility or commercialization plans are likewise exempt from ATPs business reporting requirement. The major reduction in coverage is due to failure to comply with the reporting requirement at all (approximately 15% of participants) or failure to provide information about commercialization plans (approximately 15% of participants, including universities and others in joint ventures with little commercialization intent).
Table 4 provides a profile of projects and participants by technology area. Materials-chemistry and IT have the largest number of both participants and projects. Participants/project, a density measure, shows that manufacturing and electronics/photonics have the highest average number of participants per project. Many of these projects are organized as joint ventures, with manufacturing technologybased joint ventures having more participants, on average, than others.
Table 4. Distribution of Partricipants and Projects by, Technology Area|
Technology
|
Number
of project participants
|
%
|
Number
of projects
|
%
|
Participants
per project
|
| Biotechnology |
83
|
15
|
67
|
22
|
1.2
|
| Electronics/photonics |
97
|
17
|
44
|
15
|
2.2
|
| Information technology |
140
|
25
|
73
|
24
|
1.9
|
| Manufacturing |
96
|
17
|
39
|
13
|
2.5
|
| Matrials-chemistry |
142
|
26
|
76
|
26
|
1.9
|
| Total |
558
|
100
|
299
|
100
|
1.9
|
Table 5 further profiles project participants for each technology area by type of ATP project and size/type of organization. The distributions vary considerably across technology areas. For example, two-thirds of biotechnology participants are single applicants (SAs), by far the largest proportion across any of the technologies, but 62% or more of participants in projects developing the other four technologies are members of a joint venture. Furthermore, biotechnology participants involve the largest proportion (71%) of small companies. For other technology areas, 2746% of project participants are small firms.
Table
5. Distribution of Partricipants in Each Technology Area, by Organization
Type/Size and Project Type
|
|
Firm
size
(% of participants) |
Participants
per project
(% of participants) |
||||
|
Technology
|
Number
of project participants
|
Small
|
Medium/large
|
Other*
|
SA
|
JV
|
| Biotechnology |
83
|
71
|
24
|
5
|
66
|
34
|
| Electronics/photonics |
97
|
38
|
58
|
4
|
18
|
82
|
| Information technology |
140
|
46
|
38
|
16
|
38
|
62
|
| Manufacturing |
96
|
38
|
60
|
2
|
23
|
77
|
| Matrials-chemistry |
142
|
27
|
68
|
5
|
31
|
69
|
| All |
558
|
42
|
51
|
7
|
34
|
66
|
With the exception of the biotechnology projects, most of the projects in each technology area are joint ventures. ATP-funded biotechnology firms have tended to use subcontracting mechanisms rather than a joint-venture structure to perform collaborative R&D. Many have subcontractor relationships with universities or other small firms. Many are also engaged in joint research and marketing agreements with larger biotech, pharmaceutical, or chemicals firms. The absence of joint ventures and the large number of relationships with universities likely reflect the very early-stage R&D being conducted in biotechnology and the preponderance of small firms.(2)
Table 6 shows the distribution of commercial applications by technology area. Averages per participant and project are based on the 558 participants in 299 projects; that is, no assumptions are made about projects for which no applications had yet been reported. Sixty-one percent of applications come from joint venture members and 39% from Single Applicants. The larger number of applications per project for manufacturing technologies likely reflects the larger dollar size of these projects (mainly joint ventures) and the large number of participants in many. Biotechnology projects, on the other hand, had the lowest number of planned applications per project, apparently reflecting the small number of joint ventures and the long time to market for most applications (discussed in later sections of the study). More than half of the applications came from projects developing IT or materialschemistry technologies.
Table
6. Distribution of Commercial Applications, by Technology Area
|
|
Applications
|
%
of all
|
Applications
per participant
|
Applications
per project
|
| Biotechnology |
176
|
15
|
2.1
|
2.6
|
| Electronics/photonics |
181
|
15
|
1.9
|
4.1
|
| Information technology |
307
|
26
|
2.2
|
4.2
|
| Manufacturing |
185
|
16
|
1.9
|
4.7
|
| Matrials-chemistry |
323
|
28
|
2.3
|
4.3
|
| All |
1,172
|
100
|
2.1
|
3.9
|
Most ATP projects involve development of technology platforms that support a number of different commercial applications. Participants in joint ventures often pursue a mix of their own applications and joint applications with others.
____________________
1.
For a historical, business, and R&D overview of industrial chemicals,
see Arora and Gambarella (1999).
2. Audretsch (2001) and others have noted the important
role of university scientists in biotechnology companies and the strong
ties to universities.
Return to Table of Contents or go to V. Observed Variations in Timelines for Commercialization
Date created: March
4, 2003
Last updated:
April 12, 2005
ATP website comments: webmaster-atp@nist.gov / Technical ATP inquiries: InfoCoord.ATP@nist.gov NIST is an agency of the U.S. Commerce Department |